Referencia número: HY-90005

Etravirine

(Synonyms: R165335; TMC125)

6 Cited Publications

Revisión del cliente

Based on 6 publication(s) in Google Scholar

Etravirine (R165335; TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.07%
No. CAS: 269055-15-4
Fòrmula: C₂₀H₁₅BrN₆O
Peso molecular:435.28

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Etravirine Chemical Structure

No. CAS: 269055-15-4

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Ensayo clínico
Chemical Information
Publications (6)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Etravirine (R165335; TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV.

IC₅₀ & Target

HIV-1

HIV-2

Ver todos los productos específicos de isoformas HIV :

Cellular Effect

Cell Line	Type	Value	Description	References
MDCK-II	IC₅₀	5.1 μM Compound: Etravirine	Inhibition of MRP3 expressed in MDCK2 cells assessed as cell growth inhibition by calcein and pheophorbide A efflux assays Inhibition of MRP3 expressed in MDCK2 cells assessed as cell growth inhibition by calcein and pheophorbide A efflux assays	[PMID: 21189339]
MDCK-II	IC₅₀	6 μM Compound: Etravirine	Inhibition of BCRP expressed in MDCK2 cells assessed as cell growth inhibition by calcein and pheophorbide A efflux assays Inhibition of BCRP expressed in MDCK2 cells assessed as cell growth inhibition by calcein and pheophorbide A efflux assays	[PMID: 21189339]
MDCK-II	IC₅₀	7.8 μM Compound: Etravirine	Inhibition of MRP2 expressed in MDCK2 cells assessed as cell growth inhibition by calcein and pheophorbide A efflux assays Inhibition of MRP2 expressed in MDCK2 cells assessed as cell growth inhibition by calcein and pheophorbide A efflux assays	[PMID: 21189339]
MDCK-II	IC₅₀	8.5 μM Compound: Etravirine	Inhibition of MRP1 expressed in MDCK2 cells assessed as cell growth inhibition by calcein and pheophorbide A efflux assays Inhibition of MRP1 expressed in MDCK2 cells assessed as cell growth inhibition by calcein and pheophorbide A efflux assays	[PMID: 21189339]
MDCK-II	IC₅₀	9.4 μM Compound: Etravirine	Antiproliferative activity against MDCK2 cells assessed as growth inhibition Antiproliferative activity against MDCK2 cells assessed as growth inhibition	[PMID: 21189339]
MRC5	IC₅₀	>64 μM Compound: Etravirine	Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs	[PMID: 25199582]
MRC5	IC₅₀	>64 μM Compound: Etravirine	Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay	[PMID: 25199582]
MT2	CC₅₀	>1 μM Compound: TMC-125	Cytotoxicity against MT2 cells Cytotoxicity against MT2 cells	[PMID: 16263277]
MT2	CC₅₀	>1 μM Compound: TMC-125	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 16298131]
MT2	EC₅₀	<0.002 μM Compound: TMC-125	Antiviral activity against HIV1 3B in MT2 cells by MTT assay Antiviral activity against HIV1 3B in MT2 cells by MTT assay	[PMID: 16298131]
MT2	CC₅₀	>1 μM Compound: TMC-125	Cytotoxicity against MT2 cells Cytotoxicity against MT2 cells	[PMID: 16931015]
MT2	EC₅₀	0.002 μM Compound: TMC-125	Antiviral activity against HIV1 3B in MT2 cells Antiviral activity against HIV1 3B in MT2 cells	[PMID: 16931015]
MT2	CC₅₀	75 μM Compound: 4	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 17918923]
MT2	EC₅₀	0.9 nM Compound: Etravirine	Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT2 cells Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT2 cells	[PMID: 20137928]
MT2	EC₅₀	1.6 nM Compound: Etravirine	Antiviral activity against wild type HIV1 infected in human MT2 cells Antiviral activity against wild type HIV1 infected in human MT2 cells	[PMID: 20137928]
MT2	EC₅₀	2.6 nM Compound: Etravirine	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells	[PMID: 20137928]
MT2	EC₅₀	0.9 nM Compound: Etravirine	Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT2 cells Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT2 cells	[PMID: 20138513]
MT2	EC₅₀	1.6 nM Compound: Etravirine	Antiviral activity against wild type HIV1 infected in human MT2 cells Antiviral activity against wild type HIV1 infected in human MT2 cells	[PMID: 20138513]
MT2	EC₅₀	2.6 nM Compound: Etravirine	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells	[PMID: 20138513]
MT2	CC₅₀	>0.1 μM Compound: Etravirine	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 20304641]
MT2	CC₅₀	>0.1 μM Compound: Etravirine	Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay	[PMID: 20304641]
MT2	CC₅₀	>0.1 μM Compound: Etravirine	Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay	[PMID: 20304641]
MT2	EC₅₀	0.001 μM Compound: Etravirine	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay	[PMID: 20304641]
MT2	EC₅₀	0.005 μM Compound: Etravirine	Antiviral activity against HIV1 reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay Antiviral activity against HIV1 reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay	[PMID: 20304641]
MT2	EC₅₀	0.011 μM Compound: Etravirine	Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay	[PMID: 20304641]
MT2	EC₅₀	0.058 μM Compound: 4, TMC-125	Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 20527972]
MT2	EC₅₀	0.575 μM Compound: 4, TMC-125	Antiviral activity against HIV1 with reverse transcriptase A17 (K103N, Y181C) mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against HIV1 with reverse transcriptase A17 (K103N, Y181C) mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 20527972]
MT2	EC₅₀	0.005 nM Compound: ETV, TMC-125	Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.005 multiplicities of infection after 6 days Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.005 multiplicities of infection after 6 days	[PMID: 20660667]
MT2	EC₅₀	0.05 nM Compound: ETV, TMC-125	Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.05 multiplicities of infection after 6 days Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.05 multiplicities of infection after 6 days	[PMID: 20660667]
MT2	EC₅₀	0.5 nM Compound: ETV, TMC-125	Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.5 multiplicities of infection after 6 days Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.5 multiplicities of infection after 6 days	[PMID: 20660667]
MT2	CC₅₀	50.73 μM Compound: 1, TMC-125	Cytotoxicity in human MT2 cells after 4 day by XTT assay Cytotoxicity in human MT2 cells after 4 day by XTT assay	[PMID: 21049929]
MT2	EC₅₀	0.041 μM Compound: 1, TMC-125	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as reduction in p24 antigen level after 4 days by ELISA Antiviral activity against HIV1 3B infected in human MT2 cells assessed as reduction in p24 antigen level after 4 days by ELISA	[PMID: 21049929]
MT2	EC₅₀	0.33 μM Compound: 1, TMC-125	Antiviral activity against multidrug resistant HIV1 A17 containing reverse transcripatseK103N and Y181C mutation infected in human MT2 cells assessed as reduction in p24 antigen level after 4 days by ELISA Antiviral activity against multidrug resistant HIV1 A17 containing reverse transcripatseK103N and Y181C mutation infected in human MT2 cells assessed as reduction in p24 antigen level after 4 days by ELISA	[PMID: 21049929]
MT2	CC₅₀	11 μM Compound: Etravirine	Cytotoxicity against human MT2 cells infected with HIV1 NL4.3 by MTT assay Cytotoxicity against human MT2 cells infected with HIV1 NL4.3 by MTT assay	[PMID: 22081993]
MT2	EC₅₀	0.001 μM Compound: Etravirine	Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT2 cells assessed as inhibition of viral infection Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT2 cells assessed as inhibition of viral infection	[PMID: 22081993]
MT2	EC₅₀	0.005 μM Compound: Etravirine	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase K103N and Y181C double mutant infected in human MT2 cells assessed as inhibition of viral infection Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase K103N and Y181C double mutant infected in human MT2 cells assessed as inhibition of viral infection	[PMID: 22081993]
MT2	EC₅₀	0.008 μM Compound: Etravirine	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral infection Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral infection	[PMID: 22081993]
MT2	CC₅₀	11 μM Compound: Etravirine	Cytotoxicity in human MT2 cells assessed as inhibition of cell growth Cytotoxicity in human MT2 cells assessed as inhibition of cell growth	[PMID: 23298809]
MT2	EC₅₀	0.001 μM Compound: Etravirine	Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method	[PMID: 23298809]
MT2	EC₅₀	0.005 μM Compound: Etravirine	Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase K103N and Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase K103N and Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method	[PMID: 23298809]
MT2	EC₅₀	0.008 μM Compound: Etravirine	Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method	[PMID: 23298809]
MT2	CC₅₀	11 μM Compound: Etravirine	Cytotoxicity against human MT2 cells assessed as growth inhibition Cytotoxicity against human MT2 cells assessed as growth inhibition	[PMID: 23937980]
MT2	EC₅₀	0.001 μM Compound: Etravirine	Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay	[PMID: 23937980]
MT2	EC₅₀	0.005 μM Compound: Etravirine	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay	[PMID: 23937980]
MT2	EC₅₀	0.008 μM Compound: Etravirine	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay	[PMID: 23937980]
MT2	CC₅₀	11 μM Compound: etv	Cytotoxicity against human MT2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT2 cells assessed as reduction in cell viability by MTT assay	[PMID: 25408842]
MT2	EC₅₀	0.001 μM Compound: etv	Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay	[PMID: 25408842]
MT2	EC₅₀	0.005 μM Compound: etv	Antiviral activity against wild type HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay Antiviral activity against wild type HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay	[PMID: 25408842]
MT2	EC₅₀	0.008 μM Compound: etv	Antiviral activity against wild type HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay Antiviral activity against wild type HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay	[PMID: 25408842]
MT2	CC₅₀	11 μM Compound: Etravirine	Cytotoxicity against human MT2 cells assessed as growth inhibition by MTT method Cytotoxicity against human MT2 cells assessed as growth inhibition by MTT method	[PMID: 27485603]
MT2	EC₅₀	11 μM Compound: Etravirine	Cytotoxicity against human MT2 cells assessed as cell viability by MTT assay Cytotoxicity against human MT2 cells assessed as cell viability by MTT assay	[PMID: 35175760]
MT4	IC₅₀	0.0012 μM Compound: 25	Inhibitory activity against 103N strain of HIV-I in MT-4 cells Inhibitory activity against 103N strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	0.0014 μM Compound: 25	Inhibitory activity against LAI strain of HIV-I in MT-4 cells Inhibitory activity against LAI strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	0.0033 μM Compound: 25	Inhibitory activity against 100I strain of HIV-I in MT-4 cells Inhibitory activity against 100I strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	0.0043 μM Compound: 25	Inhibitory activity against 103N strain and 181C strain of HIV-I in MT-4 cells Inhibitory activity against 103N strain and 181C strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	0.0046 μM Compound: 25	Inhibitory activity against 188L strain of HIV-I in MT-4 cells Inhibitory activity against 188L strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	0.007 μM Compound: 25	Inhibitory activity against 181C strain of HIV-I in MT-4 cells Inhibitory activity against 181C strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	0.019 μM Compound: 25	Inhibitory activity against 100I strain and 103N strain of HIV-I in MT-4 cells Inhibitory activity against 100I strain and 103N strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	EC₅₀	0.001 μM Compound: 15 (Etravirine)	Effective concentration of the compound to inhibit HIV-1 mutant K103N replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant K103N replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	0.001 μM Compound: 15 (Etravirine)	Effective concentration of the compound to inhibit HIV-1 mutant LAI replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant LAI replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	0.003 μM Compound: 15 (Etravirine)	Effective concentration of the compound to inhibit HIV-1 mutant L100I replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant L100I replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	0.004 μM Compound: 15 (Etravirine)	Effective concentration of the compound to inhibit HIV-1 mutant K103N+Y181C replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant K103N+Y181C replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	0.005 μM Compound: 15 (Etravirine)	Effective concentration of the compound to inhibit HIV-1 mutant Y188L replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant Y188L replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	0.007 μM Compound: 15 (Etravirine)	Effective concentration of the compound to inhibit HIV-1 mutant Y181C replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant Y181C replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	0.019 μM Compound: 15 (Etravirine)	Effective concentration of the compound to inhibit HIV-1 mutant L100I+K103N replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant L100I+K103N replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	IC₅₀	1 nM Compound: Etr	Antiviral activity against NNRTI-resistant HIV HXB2 isolate 14 with reverse transcriptase A98, K103, V108, M230 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 isolate 14 with reverse transcriptase A98, K103, V108, M230 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	IC₅₀	1 nM Compound: Etr	Antiviral activity against NNRTI-resistant HIV HXB2 isolate 16 with reverse transcriptase K103, P225 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 isolate 16 with reverse transcriptase K103, P225 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	IC₅₀	1 nM Compound: Etr	Antiviral activity against NNRTI-resistant HIV HXB2 isolate 47 with reverse transcriptase A98, V108, G190, F227 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 isolate 47 with reverse transcriptase A98, V108, G190, F227 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	IC₅₀	13 nM Compound: Etr	Antiviral activity against NNRTI-resistant HIV HXB2 isolate 43 with reverse transcriptase K103, Y181, P225 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 isolate 43 with reverse transcriptase K103, Y181, P225 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	IC₅₀	14 nM Compound: Etr	Antiviral activity against NNRTI-resistant HIV HXB2 isolate 17 with reverse transcriptase A98, K103, Y181 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 isolate 17 with reverse transcriptase A98, K103, Y181 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	IC₅₀	17 nM Compound: Etr	Antiviral activity against NNRTI-resistant HIV HXB2 isolate 21 with reverse transcriptase K103, V179, Y181 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 isolate 21 with reverse transcriptase K103, V179, Y181 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	IC₅₀	2 nM Compound: Etr	Antiviral activity against NNRTI-resistant HIV HXB2 isolate 1 with reverse transcriptase G190, Y188 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 isolate 1 with reverse transcriptase G190, Y188 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	IC₅₀	28 nM Compound: Etr	Antiviral activity against NNRTI-resistant HIV HXB2 isolate 2 with reverse transcriptase A98, K101, Y181, G190 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 isolate 2 with reverse transcriptase A98, K101, Y181, G190 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	IC₅₀	3 nM Compound: Etr	Antiviral activity against NNRTI-resistant HIV HXB2 isolate 29 with reverse transcriptase K103, Y181 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 isolate 29 with reverse transcriptase K103, Y181 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	IC₅₀	3 nM Compound: Etr	Antiviral activity against NNRTI-resistant HIV HXB2 isolate 36 with reverse transcriptase K103, V106, Y181 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 isolate 36 with reverse transcriptase K103, V106, Y181 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	IC₅₀	5 nM Compound: Etr	Antiviral activity against NNRTI-resistant HIV HXB2 isolate 34 with reverse transcriptase K101, V106, Y181 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 isolate 34 with reverse transcriptase K101, V106, Y181 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	IC₅₀	6 nM Compound: Etr	Antiviral activity against NNRTI-resistant HIV HXB2 isolate 12 with reverse transcriptase L100, K103 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 isolate 12 with reverse transcriptase L100, K103 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	IC₅₀	6 nM Compound: Etr	Antiviral activity against NNRTI-resistant HIV HXB2 isolate 6 with reverse transcriptase L100, K103 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 isolate 6 with reverse transcriptase L100, K103 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	IC₅₀	7 nM Compound: Etr	Antiviral activity against NNRTI-resistant HIV HXB2 isolate 20 with reverse transcriptase K103, Y181 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 isolate 20 with reverse transcriptase K103, Y181 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	IC₅₀	73 nM Compound: Etr	Antiviral activity against NNRTI-resistant HIV HXB2 isolate 31 with reverse transcriptase A98, V179, Y181 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 isolate 31 with reverse transcriptase A98, V179, Y181 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	IC₅₀	9 nM Compound: Etr	Antiviral activity against NNRTI-resistant HIV HXB2 isolate 32 with reverse transcriptase V106, V179, Y181, G190 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 isolate 32 with reverse transcriptase V106, V179, Y181, G190 mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	EC₅₀	0.00158 μM Compound: TMC-125	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral replication Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral replication	[PMID: 19666220]
MT4	EC₅₀	0.24 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype G infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype G infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	0.35 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype F1 infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype F1 infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	0.46 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype AG infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype AG infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	0.51 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype (H) infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype (H) infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	0.52 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype C infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype C infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	0.65 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype AE infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype AE infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	0.67 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype BG infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype BG infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	1.13 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype D infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype D infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	1.39 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype A1 infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype A1 infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	2.73 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	5.67 μM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	IC₅₀	1.1 nM Compound: TMC-125	Antiviral activity against HIV1 expressing reverse transcriptase G190A mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against HIV1 expressing reverse transcriptase G190A mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 20538456]
MT4	IC₅₀	2 nM Compound: TMC-125	Antiviral activity against HIV1 expressing reverse transcriptase V106A mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against HIV1 expressing reverse transcriptase V106A mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 20538456]
MT4	IC₅₀	2.1 nM Compound: TMC-125	Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect in presence of 10 % fetal bovine serum Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect in presence of 10 % fetal bovine serum	[PMID: 20538456]
MT4	IC₅₀	25.9 nM Compound: TMC-125	Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect in presence of 40 % human serum Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect in presence of 40 % human serum	[PMID: 20538456]
MT4	IC₅₀	3.1 nM Compound: TMC-125	Antiviral activity against HIV1 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against HIV1 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 20538456]
MT4	IC₅₀	9.5 nM Compound: TMC-125	Antiviral activity against HIV1 expressing reverse transcriptase K103N/L100I double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against HIV1 expressing reverse transcriptase K103N/L100I double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 20538456]
MT4	IC₅₀	2 nM Compound: Etravirine	Antiviral activity against HIV1 harboring reverse transcriptase V106A mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS Antiviral activity against HIV1 harboring reverse transcriptase V106A mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS	[PMID: 20829038]
MT4	IC₅₀	2.1 nM Compound: Etravirine	Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS	[PMID: 20829038]
MT4	IC₅₀	25.9 nM Compound: Etravirine	Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 40% human serum Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 40% human serum	[PMID: 20829038]
MT4	IC₅₀	3.1 nM Compound: Etravirine	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS	[PMID: 20829038]
MT4	IC₅₀	9.2 nM Compound: Etravirine	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS	[PMID: 20829038]
MT4	IC₅₀	9.5 nM Compound: Etravirine	Antiviral activity against HIV1 harboring reverse transcriptase K103N/L100I double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS Antiviral activity against HIV1 harboring reverse transcriptase K103N/L100I double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS	[PMID: 20829038]
MT4	CC₅₀	>4.6 μM Compound: Etravirine	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 21824782]
MT4	EC₅₀	0.003 μM Compound: Etravirine	Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 21824782]
MT4	EC₅₀	0.026 μM Compound: Etravirine	Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 21824782]
MT4	EC₅₀	0.00184 μM Compound: TMC125	Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.0046 μM Compound: TMC125	Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.008 μM Compound: TMC125	Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	CC₅₀	27.78 μM Compound: TMC125	Cytotoxicity against human MT4 cells measured by MTT assay Cytotoxicity against human MT4 cells measured by MTT assay	[PMID: 22037050]
MT4	EC₅₀	>27.78 μM Compound: TMC125	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22037050]
MT4	EC₅₀	0.0022 μM Compound: TMC125	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22037050]
MT4	EC₅₀	0.034 μM Compound: TMC125	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22037050]
MT4	EC₅₀	0.001 μM Compound: Etravirine	Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of viral infection Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of viral infection	[PMID: 22081993]
MT4	EC₅₀	0.004 μM Compound: Etravirine	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase K103N and Y181C double mutant infected in human MT4 cells assessed as inhibition of viral infection Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase K103N and Y181C double mutant infected in human MT4 cells assessed as inhibition of viral infection	[PMID: 22081993]
MT4	EC₅₀	0.007 μM Compound: Etravirine	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral infection Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral infection	[PMID: 22081993]
MT4	CC₅₀	>4.6 μM Compound: ETV, TMC125	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22405288]
MT4	EC₅₀	0.026 μM Compound: ETV, TMC125	Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 22405288]
MT4	EC₅₀	3 nM Compound: ETV, TMC125	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 22405288]
MT4	CC₅₀	28 μM Compound: ETV	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22575532]
MT4	EC₅₀	>28 μM Compound: ETV	Antiviral activity against HIV2 ROD mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22575532]
MT4	EC₅₀	0.002 μM Compound: ETV	Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22575532]
MT4	EC₅₀	0.034 μM Compound: ETV	Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22575532]
MT4	EC₅₀	0.4 nM Compound: ETR	Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay	[PMID: 23137340]
MT4	EC₅₀	0.6 nM Compound: ETR	Antiviral activity against HIV1 expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay Antiviral activity against HIV1 expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay	[PMID: 23137340]
MT4	EC₅₀	0.9 nM Compound: ETR	Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay	[PMID: 23137340]
MT4	EC₅₀	2.4 nM Compound: ETR	Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay	[PMID: 23137340]
MT4	CC₅₀	27.79 μM Compound: 2, TMC125, ETV	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 23159806]
MT4	EC₅₀	>27.79 μM Compound: 2, TMC125, ETV	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23159806]
MT4	EC₅₀	0.002 μM Compound: 2, TMC125, ETV	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23159806]
MT4	EC₅₀	0.034 μM Compound: 2, TMC125, ETV	Antiviral activity against HIV1 RES056 harbouring RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 harbouring RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23159806]
MT4	CC₅₀	>4.6 μM Compound: ETV	Cytotoxicity against mock-infected human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 23415090]
MT4	EC₅₀	0.003 μM Compound: ETV	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	[PMID: 23415090]
MT4	EC₅₀	0.026 μM Compound: ETV	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	[PMID: 23415090]
MT4	EC₅₀	1.2 nM Compound: TMC125, ETR	Antiviral activity against HIV1 harboring reverse transcriptase K101N mutant infected in human MT4 cells Antiviral activity against HIV1 harboring reverse transcriptase K101N mutant infected in human MT4 cells	[PMID: 24581546]
MT4	EC₅₀	1.4 nM Compound: TMC125, ETR	Antiviral activity against HIV1 harboring wild type reverse transcriptase infected in human MT4 cells Antiviral activity against HIV1 harboring wild type reverse transcriptase infected in human MT4 cells	[PMID: 24581546]
MT4	EC₅₀	4.3 nM Compound: TMC125, ETR	Antiviral activity against HIV1 harboring reverse transcriptase K101N/Y181C double mutant infected in human MT4 cells Antiviral activity against HIV1 harboring reverse transcriptase K101N/Y181C double mutant infected in human MT4 cells	[PMID: 24581546]
MT4	EC₅₀	7 nM Compound: TMC125, ETR	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells	[PMID: 24581546]
MT4	CC₅₀	>4.6 μM Compound: ETV, TMC125	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 24631361]
MT4	EC₅₀	0.003 μM Compound: ETV, TMC125	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay	[PMID: 24631361]
MT4	EC₅₀	0.011 μM Compound: ETV, TMC125	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay	[PMID: 24631361]
MT4	CC₅₀	27.79 μM Compound: ETV	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 24680058]
MT4	EC₅₀	>27.79 μM Compound: ETV	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	[PMID: 24680058]
MT4	EC₅₀	0.002 μM Compound: ETV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	[PMID: 24680058]
MT4	EC₅₀	0.034 μM Compound: ETV	Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	[PMID: 24680058]
MT4	CC₅₀	14.25 μM Compound: 4, ETV, TMC125	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 24794751]
MT4	EC₅₀	>14.25 μM Compound: 4, ETV, TMC125	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	[PMID: 24794751]
MT4	EC₅₀	0.002 μM Compound: 4, ETV, TMC125	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	[PMID: 24794751]
MT4	EC₅₀	0.0147 μM Compound: 4, ETV, TMC125	Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	[PMID: 24794751]
MT4	CC₅₀	11 μM Compound: TMC125	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.001 μM Compound: TMC125	Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.001 μM Compound: TMC125	Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.002 μM Compound: TMC125	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.003 μM Compound: TMC125	Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.01 μM Compound: TMC125	Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.01 μM Compound: TMC125	Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.03 μM Compound: TMC125	Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.07 μM Compound: TMC125	Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.1 μM Compound: TMC125	Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in	[PMID: 24805780]
MT4	EC₅₀	0.2 μM Compound: TMC125	Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.3 μM Compound: TMC125	Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	CC₅₀	>4.59 μM Compound: ETV	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25240095]
MT4	EC₅₀	0.0041 μM Compound: ETV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	EC₅₀	0.025 μM Compound: ETV	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	CC₅₀	>30595 nM Compound: ETV	Cytotoxic activity against human MT4 cells by MTT assay Cytotoxic activity against human MT4 cells by MTT assay	[PMID: 25418038]
MT4	EC₅₀	16 nM Compound: ETV	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	16 nM Compound: ETV	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N-Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N-Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	3.7 nM Compound: ETV	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	33 nM Compound: ETV	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	6 nM Compound: ETV	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	CC₅₀	13.32 μM Compound: ETR	Cytotoxicity against human MT4 cells after 5 days MTT assay Cytotoxicity against human MT4 cells after 5 days MTT assay	[PMID: 25537532]
MT4	EC₅₀	>13.32 μM Compound: ETR	Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	EC₅₀	0.0017 μM Compound: ETR	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	EC₅₀	0.013 μM Compound: ETR	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	CC₅₀	4.4 μM Compound: ETR	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 25626145]
MT4	EC₅₀	0.016 μM Compound: ETR	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25626145]
MT4	EC₅₀	1.8 nM Compound: ETR	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25626145]
MT4	CC₅₀	>4.6 μM Compound: ETR, TMC125	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 25707013]
MT4	EC₅₀	0.004 μM Compound: ETR, TMC125	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25707013]
MT4	EC₅₀	0.02 μM Compound: ETR, TMC125	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25707013]
MT4	CC₅₀	14.24 μM Compound: ETV, TMC125	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25907370]
MT4	EC₅₀	0.0019 μM Compound: ETV, TMC125	Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay	[PMID: 25907370]
MT4	EC₅₀	0.014 μM Compound: ETV, TMC125	Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay	[PMID: 25907370]
MT4	CC₅₀	>459 nM Compound: 1, ETV	Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay	[PMID: 25935383]
MT4	EC₅₀	25.3 nM Compound: 1, ETV	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection from virus-induced cytopathicity after 4 days by MTT assay Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection from virus-induced cytopathicity after 4 days by MTT assay	[PMID: 25935383]
MT4	EC₅₀	4.1 nM Compound: 1, ETV	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathicity after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathicity after 4 days by MTT assay	[PMID: 25935383]
MT4	CC₅₀	>4.6 μM Compound: 1, ETV, TMC125	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days MTT method Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days MTT method	[PMID: 26162497]
MT4	EC₅₀	0.0041 μM Compound: 1, ETV, TMC125	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity incubated for 4 days by MTT method Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity incubated for 4 days by MTT method	[PMID: 26162497]
MT4	EC₅₀	0.025 μM Compound: 1, ETV, TMC125	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity incubated for 4 days by MTT method Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity incubated for 4 days by MTT method	[PMID: 26162497]
MT4	CC₅₀	>4595 nM Compound: 4, ETV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay	[PMID: 26276435]
MT4	EC₅₀	25.3 nM Compound: 4, ETV	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method Antiviral activity against HIV1 3B expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method	[PMID: 26276435]
MT4	EC₅₀	4.1 nM Compound: 4, ETV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method	[PMID: 26276435]
MT4	CC₅₀	>4.59 μM Compound: Etravirine	Cytotoxicity against uninfected human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against uninfected human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 26385446]
MT4	EC₅₀	0.0041 μM Compound: Etravirine	Antiviral activity against wild type HIV 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 26385446]
MT4	EC₅₀	0.011 μg/mL Compound: Etravirine	Antiviral activity against HIV 1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV 1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 26385446]
MT4	EC₅₀	0.0032 μM Compound: ETV	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.0035 μM Compound: ETV	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.0066 μM Compound: ETV	Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.014 μM Compound: ETV	Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.016 μM Compound: ETV	Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.0172 μM Compound: ETV	Antiviral activity against HIV1 RES056 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.022 μM Compound: ETV	Antiviral activity against HIV1 3B expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	CC₅₀	2.16 μM Compound: ETV	Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay	[PMID: 26994843]
MT4	EC₅₀	0.0039 μM Compound: ETV	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	[PMID: 26994843]
MT4	EC₅₀	0.034 μM Compound: ETV	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	[PMID: 26994843]
MT4	CC₅₀	>4.5 μM Compound: TMC125	Cytotoxicity against human MT4 cells after 5 days MTT assay Cytotoxicity against human MT4 cells after 5 days MTT assay	[PMID: 27112451]
MT4	EC₅₀	0.004 μM Compound: TMC125	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27112451]
MT4	CC₅₀	>4.6 μM Compound: ETR	Cytotoxicity against mock-infected human MT4 cells Cytotoxicity against mock-infected human MT4 cells	[PMID: 27234889]
MT4	EC₅₀	0.0032 μM Compound: ETR	Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	EC₅₀	0.011 μM Compound: ETR	Antiviral activity against HIV-1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	CC₅₀	>4.6 μM Compound: ETV	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27267005]
MT4	EC₅₀	0.0095 μM Compound: ETV	Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27267005]
MT4	EC₅₀	0.02 μM Compound: ETV	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27267005]
MT4	CC₅₀	5.88 μM Compound: Etravirine	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by cell titer glo based luciferase reporter gene assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by cell titer glo based luciferase reporter gene assay	[PMID: 27371922]
MT4	EC₅₀	0.002 μM Compound: Etravirine	Inhibition of HIV-1 3B reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay Inhibition of HIV-1 3B reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay	[PMID: 27371922]
MT4	EC₅₀	0.002 μM Compound: Etravirine	Inhibition of wild type HIV-1 3B reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay Inhibition of wild type HIV-1 3B reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay	[PMID: 27371922]
MT4	EC₅₀	0.012 μM Compound: Etravirine	Inhibition of reverse transcriptase Y181C mutant in HIV-1 3B infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay Inhibition of reverse transcriptase Y181C mutant in HIV-1 3B infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay	[PMID: 27371922]
MT4	CC₅₀	2.46 μM Compound: ETV; TMC125	Cytotoxicity against mock-infected human MT4 cells assessed as reduction of cell viability after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction of cell viability after 5 days by MTT assay	[PMID: 27501911]
MT4	CC₅₀	>4590 nM Compound: ETV	Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	14.4 nM Compound: ETV	Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	15.8 nM Compound: ETV	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	17 nM Compound: ETV	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	2.4 nM Compound: ETV	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	20.5 nM Compound: ETV	Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	29.4 nM Compound: ETV	Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	4.1 nM Compound: ETV	Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	5.4 nM Compound: ETV	Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	CC₅₀	2.2 μM Compound: ETV	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 27750153]
MT4	CC₅₀	2.46 μM Compound: ETV	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 28254696]
MT4	CC₅₀	1.9 μM Compound: 1; TMC125	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 28314514]
MT4	CC₅₀	>4.6 μM Compound: Etravirine	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 28314598]
MT4	CC₅₀	>0.00459 μM Compound: ETV	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 28481112]
MT4	CC₅₀	>22973 nM Compound: ETR	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 28628334]
MT4	CC₅₀	2.15 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 28659246]
MT4	CC₅₀	>4.59 μM Compound: ETR; TMC125	Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 28987601]
MT4	CC₅₀	2.18 μM Compound: 1; ETV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 29152052]
MT4	CC₅₀	>2000 nM Compound: 2; ETV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 29353724]
MT4	CC₅₀	>4.59 μM Compound: ETR	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 29534929]
MT4	CC₅₀	2.15 μM Compound: 2, TMC125, ETV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 29559197]
MT4	CC₅₀	2.46 μM Compound: ETR; TMC125	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 29635166]
MT4	CC₅₀	2.2 μM Compound: 4; ETV	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 29670696]
MT4	CC₅₀	2.155 μM Compound: ETV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 29670703]
MT4	CC₅₀	>2 μM Compound: ETV; 1	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 30318436]
MT4	CC₅₀	3500 nM Compound: TMC125	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 30525601]
MT4	CC₅₀	>4.59 μM Compound: ETV	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 30624934]
MT4	CC₅₀	>4.59 μM Compound: ETR, TMC125; 1	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 30721060]
MT4	CC₅₀	>2 μM Compound: 2; ETV	Cytotoxicity against human MT4 cells measured after 5 days by MTT assay Cytotoxicity against human MT4 cells measured after 5 days by MTT assay	[PMID: 31091477]
MT4	CC₅₀	>4.61 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay	[PMID: 31421633]
MT4	CC₅₀	>4.61 μM Compound: 4; ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31434039]
MT4	CC₅₀	>4.61 μM Compound: 1; ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31714780]
MT4	CC₅₀	>4.59 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31735575]
MT4	CC₅₀	>87 μM Compound: Etravirine	Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay	[PMID: 31767136]
MT4	CC₅₀	>4.58 μM Compound: 1; ETR	Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31935327]
MT4	CC₅₀	>4.59 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 32200201]
MT4	CC₅₀	>4.59 μM Compound: 1; ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 32293182]
MT4	CC₅₀	>4.59 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 32712537]
MT4	CC₅₀	>22973 nM Compound: ETR	Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay	[PMID: 32883642]
MT4	CC₅₀	>4.59 μM Compound: 4; ETV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 32977301]
MT4	CC₅₀	>4.59 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 33279288]
MT4	CC₅₀	>4.6 μM Compound: 4; ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 33340914]
MT4	CC₅₀	>4.594 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 33567378]
MT4	CC₅₀	>4.59 μM Compound: 1; ETR	Cytotoxicity in mock-infected human MT4 assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity in mock-infected human MT4 assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 33734714]
MT4	CC₅₀	>4.6 μM Compound: 1; ETR	Cytotoxicity against in human MT-4 cells after 5 days by MTT assay Cytotoxicity against in human MT-4 cells after 5 days by MTT assay	[PMID: 33851529]
MT4	CC₅₀	>4.59 μM Compound: Etravirine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 33979774]
MT4	CC₅₀	>4.61 μM Compound: ETR	Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay	[PMID: 34090079]
MT4	CC₅₀	>4.6 μM Compound: ETR; 1	Cytotoxicity against mock infected human MT4 cells by MTT assay Cytotoxicity against mock infected human MT4 cells by MTT assay	[PMID: 34197708]
MT4	CC₅₀	>4.59 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 34432448]
MT4	CC₅₀	>4.6 μM Compound: ETR	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 34496571]
MT4	CC₅₀	>4590 nM Compound: ETV	Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 34890994]
MT4	CC₅₀	>4.59 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 35061384]
MT4	CC₅₀	>4.6 μM Compound: 1; ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 35073089]
MT4	CC₅₀	>4620 nM Compound: Etravirine	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 35175760]
MT4	CC₅₀	>4.59 μM Compound: ETV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay	[PMID: 35640327]
MT4	CC₅₀	>4.6 μM Compound: Etravirine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 35649164]
MT4	CC₅₀	4.6 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay	[PMID: 35679690]
MT4	CC₅₀	>4.6 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as reduction on cell growth by MTT assay Cytotoxicity against human MT4 cells assessed as reduction on cell growth by MTT assay	[PMID: 35797898]
MT4	CC₅₀	>4.61 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 36411036]
MT4	CC₅₀	>4.6 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay	[PMID: 36446205]
MT4	CC₅₀	>4.59 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 36577216]
MT4	CC₅₀	>4.6 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT spectrophotometric assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT spectrophotometric assay	[PMID: 36640458]
MT4	CC₅₀	7.3 μM Compound: ETV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by Cell Titer Glo luminescent assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by Cell Titer Glo luminescent assay	[PMID: 36652602]
MT4	CC₅₀	>4.59 μM Compound: ETR; 1	Cytotoxicity against human MT4 cells assessed as reduction in cell viability treated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability treated for 5 days by MTT assay	[PMID: 36700940]
MT4	CC₅₀	>4.61 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 36996328]
MT4	CC₅₀	>4.61 μM Compound: ETR; 1	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 37255025]
MT4	CC₅₀	>4.59 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 37393790]
MT4	CC₅₀	>4.6 μM Compound: 4; ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 37536208]
MT4	CC₅₀	>461 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 37976805]
MT4	CC₅₀	>4.61 μM Compound: 1; ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 38996652]
MT4	CC₅₀	>4.59 μM Compound: 1; ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 39094273]
MT4	CC₅₀	>4.595 μM Compound: ETR	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT method Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT method	[PMID: 39167895]
PBMC	EC₅₀	0.21 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype E isolate 93TH073 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype E isolate 93TH073 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.43 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype B isolate WEJO infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype B isolate WEJO infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.44 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG035 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG035 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.46 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR019 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR019 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.48 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92RW020 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92RW020 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.5 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype E isolate 92TH006 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype E isolate 92TH006 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.66 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype G isolate G3 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype G isolate G3 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.9 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG001 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG001 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	1.01 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 93MW959 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 93MW959 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	1.02 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype B isolate JR-CSF infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype B isolate JR-CSF infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	1.06 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR029 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR029 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	1.08 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR020 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR020 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	1.35 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype B isolate 93BR021 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype B isolate 93BR021 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	1.42 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92UG037 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92UG037 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	1.45 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92UG029 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92UG029 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	1.45 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype G isolate JV1083 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype G isolate JV1083 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	1.7 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 92BR025 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 92BR025 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	1.7 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype G isolate RU132 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype G isolate RU132 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	149 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype O isolate BCF03 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype O isolate BCF03 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	16.4 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype O misolate BCF01 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype O misolate BCF01 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	2.72 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 93IN101 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 93IN101 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	3.18 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG024 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG024 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	3.47 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype E isolate CMU08 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype E isolate CMU08 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	52.8 nM Compound: ETR, TMC-125	Antiviral activity against Human immunodeficiency virus 1 subtype O isolate BCF02 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype O isolate BCF02 infected in human PBMC cells by cell based assay	[PMID: 19933797]
TZM	CC₅₀	8.96 μM Compound: 1, TMC-125	Cytotoxicity in human TZM-bl cells after 4 day by XTT assay Cytotoxicity in human TZM-bl cells after 4 day by XTT assay	[PMID: 21049929]
TZM	CC₅₀	>25 μM Compound: Etravirine	Cytotoxicity against human TZM-bl cells assessed as cell viability after 48 hrs by WST1 assay Cytotoxicity against human TZM-bl cells assessed as cell viability after 48 hrs by WST1 assay	[PMID: 25199582]
TZM	CC₅₀	>229 nM Compound: 4; ETR	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 1 day by CytoTox-Glo assay Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 1 day by CytoTox-Glo assay	[PMID: 33340914]

In Vitro

TMC125 is highly active against wild-type HIV-1 (50% effective concentration [EC₅₀]=1.4 to 4.8 nM) and shows some activity against HIV-2 (EC₅₀=3.5 μM). TMC125 also inhibits a series of HIV-1 group M subtypes and circulating recombinant forms and a group O virus. TMC125 has activity for 19 viruses with EC₅₀ of < 5 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 269055-15-4
Appearance Solid
Peso molecular 435.28
Fòrmula C₂₀H₁₅BrN₆O
Color White to off-white
SMILES

N#CC1=CC(C)=C(C(C)=C1)OC2=NC(NC3=CC=C(C=C3)C#N)=NC(N)=C2Br
Synonyms

R165335; TMC125
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (6)

All

Sort by:

Journal Impact Factor

Pharmaceuticals (Basel)

Combined In Silico and In Vitro Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells. [Abstract]

2022 Sep 25;15(10):1186. PMID: 36297298
Int J Antimicrob Agents

Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro. [Abstract]

2019 Dec;54(6):814-819. PMID: 31479744
Sci Rep

NMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities. [Abstract]

2015 Oct 29:5:15806. PMID: 26510386
Antimicrob Agents Chemother

Effects of Antiviral Drugs on Organic Anion Transport in Human Placental BeWo Cells. [Abstract]

2015 Dec;59(12):7666-70. PMID: 26416870
Biol Pharm Bull

Mass Spectrometric Characterization of HIV-1 Reverse Transcriptase Interactions with Non-nucleoside Reverse Transcriptase Inhibitors. [Abstract]

2016;39(3):450-4. PMID: 26934936
chemRxiv

2026 Apr 6.

Solvente y solubilidad

In Vitro:

DMSO : 50 mg/mL (114.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2974 mL

11.4869 mL

22.9737 mL

5 mM

0.4595 mL

2.2974 mL

4.5947 mL

10 mM

0.2297 mL

1.1487 mL

2.2974 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (276 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Andries, K., et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother, 2004. 48(12): p. 468 [Content Brief]

[2]. Lazzarin, A., et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 2007. 370(9581): p. 39-48. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2974 mL	11.4869 mL	22.9737 mL	57.4343 mL
	5 mM	0.4595 mL	2.2974 mL	4.5947 mL	11.4869 mL
	10 mM	0.2297 mL	1.1487 mL	2.2974 mL	5.7434 mL
	15 mM	0.1532 mL	0.7658 mL	1.5316 mL	3.8290 mL
	20 mM	0.1149 mL	0.5743 mL	1.1487 mL	2.8717 mL
	25 mM	0.0919 mL	0.4595 mL	0.9189 mL	2.2974 mL
	30 mM	0.0766 mL	0.3829 mL	0.7658 mL	1.9145 mL
	40 mM	0.0574 mL	0.2872 mL	0.5743 mL	1.4359 mL
	50 mM	0.0459 mL	0.2297 mL	0.4595 mL	1.1487 mL
	60 mM	0.0383 mL	0.1914 mL	0.3829 mL	0.9572 mL
	80 mM	0.0287 mL	0.1436 mL	0.2872 mL	0.7179 mL
	100 mM	0.0230 mL	0.1149 mL	0.2297 mL	0.5743 mL

Keywords

Etravirine

6 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Etravirine

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Rare Diseases Drug Library

EMA-Approved Drug Library

Non-steroidal Anti-Inflammatory Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Nephrotoxicity Compound Library

Anti-Infection Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Etravirine

Ver todos los productos específicos de isoformas HIV

Actividad biológica

Chemical Information

Publications (6)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Etravirine

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Rare Diseases Drug Library

EMA-Approved Drug Library

Non-steroidal Anti-Inflammatory Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Nephrotoxicity Compound Library

Anti-Infection Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Etravirine

Ver todos los productos específicos de isoformas HIV

Actividad biológica

Chemical Information

Publications (6)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Etravirine Related Classifications

HY-90005 Related Classifications